Board of Directors

Kees Lucas, Ph.D;

Non-Executive Chairman of the Board

Kees spent five years at Biogen Idec where he was part of the senior management team. Kees led the team that wrote the oncology strategy for Biogen, before the merger with Idec Pharmaceuticals. After 5 years as Senior Director Corporate Development he left Biogen-Idec, to become an independent consultant for the biotech industry. Kees has a long and distinguished career in science, pharmaceuticals and business development. He holds a Biochemistry Degree from the University of Delft and a Ph.D. degree in Medicine from Amsterdam University. Kees completed his Management training at IMD, Lausanne, before becoming part-time professor in Neuro-immunology at Amsterdam Free University, where he earned an Emeritus status since through 2010. He worked in immunological research (auto-immunity, vaccines, cancer immunotherapy, transplantation) at the research center of the Dutch Blood Transfusion Service (now ‘Sanquin’).

He is a Non-Executive Director of several biotech companies and has a multitude of experience in working with various companies worldwide. His corporate track- includes Chiron, Novartis, Norwood, Bionest, Parteurop, Theraptosis, Faust, Imaxio, Erytech, Envivo, Kempen&Co, Pharmexa, DNAge, CMP Therapeuticals, Inventages, HLA-G technologies, Synvolux and Pfizer. He also works for several VC’s and investment banks.

Kees is a citizen of the world and is a respected worldwide key Opinion Leader. He was a member of the Health Council for the For the Dutch government and he represented The Netherlands in UN conferences on de-armament and biological weapons. He was closely involved in worldwide activities around Children’s Vaccines Initiative (CVI, later GAVI). He was also a Key Opinion Leader on Multiple Sclerosis through a large part of his career and was personally responsible for the formation of the Multiple Sclerosis Foundation in the Netherlands for which he received Dutch Royal recognition.

Read More

Pedro de Noronha Pissarra, Ph.D.

Chief Executive Officer, Biotecnol Limited

Pedro obtained both his B.Sc. and Ph.D. in Biotechnology from Kings College London (University of London). He carried out research at several institutions, including the Chemical Engineering Department of Massachusetts Institute of Technology (M.I.T.), Cambridge, USA and at the Centre for Process Biotechnology (CPB) of the Technical University of Denmark, Lyngby, Denmark. Following his Doctoral degree he specialized in medical sciences and oncology. After his Postdoctoral training he undertook a 12 month Masters Programme in Management at the IC2 Institute of the University of Texas, Austin, USA.

Pedro was a visiting professor at the Catholic University of Porto during 2000-2007 where he delivered lectures in biopharmaceutical sciences. He was the Chairman & Chief Executive Officer of Biotecnol SA, in Lisbon Portugal, up to March 2012. He currently holds the position of Executive Chairman and is an integral part of its Board of Directors. Prior to his current position he was a Board Member of Vida Rhein Corporation SA – a German-Portuguese joint venture, part of the Rhein Biotech NV group, dedicated to the development of Hepatitis B vaccines and other biosimilar products.

Pedro was the founder of the Portuguese Bio-industries Association (APBio) and later had it incorporated into EuropaBio (the European Bioindustries Association). Between 1998 and 2005 he was the Chairman of APBio, and has been widely recognized as one of the key individuals in establishing and promoting the biotechnology industry in Portugal. Between 1997 and 2000 he was a member of the Advisory Group of the Biotechnology & Finance Forum, organized by the European Association of Security Dealers and Automated Quotations (EASDAQ), and the European Commission’s DG Research. He was a member of the National Council of the National Entrepreneurs Association (ANJE). Pedro was extensively involved in several EuropaBio initiatives and task forces. For several years he was a member of the Policy & Operations Council and Coordination Council, the Emerging Enterprises Sub-Board and the Biosimilar Products Task-Force.

He has been involved since 1997 in several expert panels advising the European Commission in its biotechnology policies. He has also been involved in several Advisory Committees for the Portuguese Government. Pedro was a member of the Superior Counsel for Science, Technology and Innovation for the Portuguese Government, where he advised the Minister of Science and Technology in the implementation of the National Innovation Plan during the mandate of Dr. José Manuel Durão Barroso as Prime Minister of Portugal. Other recognitions included his participation in the Honor committee of the President of the Republic of Portugal, Prof. Aníbal Cavaco Silva in 2006.

Pedro has been awarded the Medal of Merit by the Oeiras Council in Portugal in recognition for his role in promoting entrepreneurship and for services provided to the council of Oeiras, where Biotecnol SA, the biotech pioneer in Portugal started its operations and is present since 1997.

Read More

Neill Moray Mackenzie, Ph.D.

Chief Business Officer, Biotecnol Limited

Neill is an internationally networked pharmaceutical executive with an extensive operational, business, commercial, licensing and R&D background in a range of therapeutic areas. He holds a PhD in immunology and post-doctoral work at the National Institute for Medical Research with the MRC. He joined Wellcome plc as Head of the Immunology Department continuing with Mallinckrodt Inc.

Over the last eighteen years, he has served on the Boards of listed (both the full London Stock Exchange (LSE) and the Alternative Investment Market (AIM)) and private companies in the UK and Germany as an Executive Director with P&L responsibilities, and has raised over $150 million equity capital from private and public funds.

Read More

Nigel Blackburn, Ph.D

Observer to the Board of Directors on behalf of CRUK

Nigel leads the Centre for Drug Development (CDD) at CRUK and is responsible for CRUK's early drug development programmes, which include pre-clinical development and early clinical testing of novel anti-cancer agents. Nigel and his team at the CDD are currently managing the early development of over 20 novel agents. Nigel joined CRUK in May 2009 as Director of Drug Development, having previously held a variety of senior leadership roles in the pharma and biotech industries. He has experience of all phases of clinical drug development and a broad range of therapeutic modalities and disease areas. Nigel holds a biochemistry degree and PhD in physiology.